ES2858753T3 - Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer - Google Patents
Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer Download PDFInfo
- Publication number
- ES2858753T3 ES2858753T3 ES17752742T ES17752742T ES2858753T3 ES 2858753 T3 ES2858753 T3 ES 2858753T3 ES 17752742 T ES17752742 T ES 17752742T ES 17752742 T ES17752742 T ES 17752742T ES 2858753 T3 ES2858753 T3 ES 2858753T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- optionally substituted
- formula
- alkyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *N(CC1)CCC1=O Chemical compound *N(CC1)CCC1=O 0.000 description 11
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297522P | 2016-02-19 | 2016-02-19 | |
| PCT/IB2017/000237 WO2017141116A1 (en) | 2016-02-19 | 2017-02-17 | Carboxamide derivatives useful as rsk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2858753T3 true ES2858753T3 (es) | 2021-09-30 |
Family
ID=59625645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17752742T Active ES2858753T3 (es) | 2016-02-19 | 2017-02-17 | Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9771366B2 (enExample) |
| EP (2) | EP3416964B1 (enExample) |
| JP (2) | JP6912486B2 (enExample) |
| KR (1) | KR102746242B1 (enExample) |
| CN (2) | CN109071542B (enExample) |
| AU (1) | AU2017220738B2 (enExample) |
| CO (1) | CO2018008846A2 (enExample) |
| DK (1) | DK3416964T3 (enExample) |
| ES (1) | ES2858753T3 (enExample) |
| IL (1) | IL261170B (enExample) |
| MX (1) | MX376974B (enExample) |
| PL (1) | PL3416964T3 (enExample) |
| PT (1) | PT3416964T (enExample) |
| WO (1) | WO2017141116A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201202319D0 (en) | 2012-02-10 | 2012-03-28 | Orbsen Therapeutics Ltd | Stromal stem cells |
| WO2016150884A1 (en) | 2015-03-20 | 2016-09-29 | Orbsen Therapeutics Limited | Modulators of syndecan-2 and uses thereof |
| CA2990521C (en) | 2015-07-07 | 2023-10-10 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
| US11918687B2 (en) | 2016-01-15 | 2024-03-05 | Orbsen Therapeutics Limited | SDC-2 exosome compositions and methods of isolation and use |
| WO2017141116A1 (en) * | 2016-02-19 | 2017-08-24 | Phoenix Molecular Designs | Carboxamide derivatives useful as rsk inhibitors |
| AU2018300272B2 (en) | 2017-07-14 | 2024-09-19 | Orbsen Therapeutics Limited | CD39 stromal stem cells methods of isolation and use |
| BR112020024019A2 (pt) | 2018-05-25 | 2021-02-23 | Imara Inc. | monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona |
| KR20250108770A (ko) | 2018-08-31 | 2025-07-15 | 카듀리온 파마슈티칼스, 인크. | 겸상 세포 질환의 치료를 위한 pde9 억제제 |
| CN109847063B (zh) * | 2018-12-26 | 2023-02-28 | 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） | Rsk信号通路抑制剂在抑制沙眼衣原体感染中的应用 |
| CN109438403A (zh) * | 2018-12-28 | 2019-03-08 | 凯瑞斯德生化(苏州)有限公司 | 一种5-氨基苯并呋喃-2-甲酸乙酯的制备方法 |
| US12378245B2 (en) | 2019-02-11 | 2025-08-05 | Phoenix Molecular Designs | Crystalline forms of an RSK inhibitor |
| TW202307005A (zh) * | 2021-05-28 | 2023-02-16 | 美商邊際分析公司 | 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法 |
| SMT202500447T1 (it) | 2021-11-02 | 2026-01-12 | Flare Therapeutics Inc | Agonisti inversi di pparg e loro usi |
| US20260193283A1 (en) * | 2022-06-07 | 2026-07-09 | Kinoteck Therapeutics Co., Ltd. | Carboxamide derivative having rsk inhibitory effect, pharmaceutical composition comprising same, and use thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| JP2001501946A (ja) | 1996-10-08 | 2001-02-13 | イーライ・リリー・アンド・カンパニー | 新規セロトニン５―ｈｔ▲下１ｆ▼アゴニスト |
| ZA979961B (en) * | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
| AU741482B2 (en) | 1997-05-07 | 2001-11-29 | Allergan Pharmaceuticals International Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| EP1495016A2 (en) * | 2002-04-09 | 2005-01-12 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
| US20050032869A1 (en) * | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CA2881078C (en) * | 2004-06-24 | 2018-10-02 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US7790712B2 (en) | 2005-03-17 | 2010-09-07 | Boehringer Ingelheim Pharmaceutical, Inc. | Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors |
| FR2884516B1 (fr) | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| CA2690410C (en) * | 2007-06-12 | 2015-09-29 | Provid Pharmaceuticals, Inc. | Kinase inhibitors, compositions thereof, and methods of use therewith |
| NZ583689A (en) | 2007-09-14 | 2012-04-27 | Univ Michigan | F1f0-atpase inhibitors and related methods |
| GB0718870D0 (en) | 2007-09-27 | 2007-11-07 | Univ Dundee | Modulation of RSK |
| WO2011071725A1 (en) * | 2009-12-07 | 2011-06-16 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core |
| US9150577B2 (en) | 2009-12-07 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing an indole core |
| WO2013181742A1 (en) | 2012-06-04 | 2013-12-12 | Phoenix Molecular Diagnostics Ltd. | Methods of inhibiting rsk for treatment of breast cancer |
| EP2943485B1 (en) * | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| CN103724251B (zh) * | 2014-01-18 | 2015-07-22 | 福州大学 | 一种靶向stat3的小分子化合物及其制备方法和应用 |
| CA2944610C (en) | 2014-04-07 | 2024-01-09 | Netherlands Translational Research Center B.V. | (5,6-dihydro)pyrimido[4,5-e]indolizines |
| WO2017141116A1 (en) | 2016-02-19 | 2017-08-24 | Phoenix Molecular Designs | Carboxamide derivatives useful as rsk inhibitors |
-
2017
- 2017-02-17 WO PCT/IB2017/000237 patent/WO2017141116A1/en not_active Ceased
- 2017-02-17 JP JP2018543101A patent/JP6912486B2/ja active Active
- 2017-02-17 CN CN201780024735.XA patent/CN109071542B/zh active Active
- 2017-02-17 PL PL17752742T patent/PL3416964T3/pl unknown
- 2017-02-17 EP EP17752742.1A patent/EP3416964B1/en active Active
- 2017-02-17 CN CN202110838177.9A patent/CN113620950A/zh active Pending
- 2017-02-17 AU AU2017220738A patent/AU2017220738B2/en active Active
- 2017-02-17 PT PT177527421T patent/PT3416964T/pt unknown
- 2017-02-17 KR KR1020187027085A patent/KR102746242B1/ko active Active
- 2017-02-17 ES ES17752742T patent/ES2858753T3/es active Active
- 2017-02-17 US US15/436,587 patent/US9771366B2/en active Active
- 2017-02-17 DK DK17752742.1T patent/DK3416964T3/da active
- 2017-02-17 EP EP20211105.0A patent/EP3848373A1/en not_active Withdrawn
- 2017-02-17 MX MX2018010028A patent/MX376974B/es active IP Right Grant
- 2017-02-17 US US16/077,029 patent/US10758530B2/en active Active
- 2017-07-31 US US15/665,181 patent/US10081632B2/en active Active
-
2018
- 2018-08-15 IL IL261170A patent/IL261170B/en unknown
- 2018-08-24 CO CONC2018/0008846A patent/CO2018008846A2/es unknown
-
2020
- 2020-06-30 US US16/917,595 patent/US20210186961A1/en not_active Abandoned
-
2021
- 2021-07-06 JP JP2021112227A patent/JP7289876B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7289876B2 (ja) | Ｒｓｋ阻害剤として有用なカルボキサミド誘導体 | |
| ES2946507T3 (es) | Imidazolonilquinolinas y su uso como inhibidores de ATM cinasa | |
| ES2872555T3 (es) | Inhibidores de HPK1 y métodos de uso de los mismos | |
| ES2930312T3 (es) | Uso de un derivado de pteridinona como inhibidor del EGFR | |
| ES2888473T3 (es) | Bencimidazoles sustituidos con isoxazolilo | |
| ES2726717T3 (es) | Imidazopiridinas sustituidas con isoxazolilo | |
| ES2560611T3 (es) | Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK | |
| ES3011282T3 (en) | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits | |
| ES2953576T3 (es) | Moduladores del receptor beta-3 adrenérgico útiles para el tratamiento o la prevención de la insuficiencia cardíaca y los trastornos relacionados con la misma | |
| ES2528447T3 (es) | Derivados de pirazoloquinolina como inhibidores de ADN-PK | |
| ES2709034T3 (es) | Pirimido[4,5-b]quinolina-4,5 (3h,10h)-dionas como supresores de mutaciones sin sentido | |
| ES2366489T9 (es) | Compuestos de pirido (2, 3-D) piridinona y sus uso como inhibidores de PI3 | |
| ES3037417T3 (en) | Purine derivatives as sik-3 inhibitors | |
| KR20220028075A (ko) | 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도 | |
| ES2743701T3 (es) | Conjugados de ligando-fármaco del receptor sigma-2 como compuestos antitumorales, métodos de síntesis y usos de los mismos | |
| CA3099148A1 (en) | Inhibitors of the ras oncoprotein, methods of making and methods of use thereof | |
| BR112019003973A2 (pt) | inibição de atividade olig2 | |
| ES2893001T3 (es) | Nuevos derivados de dihidropiranopirimidinona y su uso | |
| ES2966719T3 (es) | Derivados de quinazolina-2,4-diona como inhibidores de PARP | |
| CA3014395C (en) | Carboxamide derivatives useful as rsk inhibitors | |
| BR112018016968B1 (pt) | Composto,composição farmacêutica e uso do mesmo para preparo de um medicamento para tratamento de câncer | |
| ES2263033T3 (es) | Derivados de pirodoindolona sustituidos en posicion 3 con un grupo heterociclico, su preparacion y su aplicacion en terapeutica. | |
| HK1260540B (en) | Carboxamide derivatives useful as rsk inhibitors | |
| HK1260540A1 (en) | Carboxamide derivatives useful as rsk inhibitors | |
| CN115023228A (zh) | 组合 |